135 related articles for article (PubMed ID: 21738115)
1. The Vienna protocol and perspectives in radionuclide therapy.
Sinzinger H; Palumbo B; Ozker K
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):420-30. PubMed ID: 21738115
[TBL] [Abstract][Full Text] [Related]
2. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy and integrated protocols for bone metastases.
Chiacchio S; Mazzarri S; Lorenzoni A; Nyakale N; Boni G; Borsò E; Alsharif A; Grosso M; Manca G; Greco C; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):431-47. PubMed ID: 21738116
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
Dolezal J
Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
[TBL] [Abstract][Full Text] [Related]
5. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
Sinzinger H; Weiss K; Hiltunen J
Anticancer Res; 2009 Aug; 29(8):3393-5. PubMed ID: 19661362
[TBL] [Abstract][Full Text] [Related]
6. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
8.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
9. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
11. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
12. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.
Baczyk M; Czepczyński R; Milecki P; Pisarek M; Oleksa R; Sowiński J
Nucl Med Commun; 2007 Apr; 28(4):245-50. PubMed ID: 17325585
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
14. [Radionuclide therapy for painful bone metastases].
Szefer J; Zuchora Z
Wiad Lek; 2004; 57(5-6):280-3. PubMed ID: 15518077
[TBL] [Abstract][Full Text] [Related]
15. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
17. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study.
Agarwal KK; Singla S; Arora G; Bal C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):79-88. PubMed ID: 25070686
[TBL] [Abstract][Full Text] [Related]
18. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.
Ricci S; Boni G; Pastina I; Genovesi D; Cianci C; Chiacchio S; Orlandini C; Grosso M; Alsharif A; Chioni A; Di Donato S; Francesca F; Selli C; Rubello D; Mariani G
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1023-30. PubMed ID: 17242920
[TBL] [Abstract][Full Text] [Related]
20. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]